Home >> Signaling Pathways >> PI3K/Akt/mTOR Signaling

PI3K/Akt/mTOR Signaling

  1. Cat.No. Product Name Information
  2. GC68429 GNE-490 GNE-490  Chemical Structure
  3. GC68413 CYH33 CYH33  Chemical Structure
  4. GC68219 L-Leucine-13C L-Leucine-13C  Chemical Structure
  5. GC68037 L-Leucine-1-13C,15N L-Leucine-1-13C,15N  Chemical Structure
  6. GC67961 AMPK-IN-3 AMPK-IN-3  Chemical Structure
  7. GC67954 PI3K-IN-36 PI3K-IN-36  Chemical Structure
  8. GC67772 BAY-3827 BAY-3827  Chemical Structure
  9. GC67700 AKT Kinase Inhibitor hydrochloride AKT Kinase Inhibitor hydrochloride  Chemical Structure
  10. GC52443 Akt Substrate (trifluoroacetate salt) An Akt peptide substrate Akt Substrate (trifluoroacetate salt)  Chemical Structure
  11. GC52387 Crosstide (trifluoroacetate salt) A peptide substrate for Akt Crosstide (trifluoroacetate salt)  Chemical Structure
  12. GC66474 PDK1-IN-RS2 PDK1-IN-RS2 is a mimic of peptide docking motif (PIFtide) and is a substrate-selective PDK1 inhibitor with a Kd of 9 μM. PDK1-IN-RS2 suppresses the activation of the downstream kinases S6K1 by PDK1. PDK1-IN-RS2  Chemical Structure
  13. GC66463 PI3K/Akt/mTOR-IN-2 PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis. PI3K/Akt/mTOR-IN-2  Chemical Structure
  14. GC66447 PI3K/mTOR Inhibitor-4 PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer. PI3K/mTOR Inhibitor-4  Chemical Structure
  15. GC66357 L-Leucine-d2 L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. L-Leucine-d2  Chemical Structure
  16. GC66065 MELK-IN-1 MELK-IN-1 is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK) with an IC50 and a Ki of 3 nM and 0.39 nM, respectively. MELK-IN-1  Chemical Structure
  17. GC66035 GSK3-IN-1 GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC50 value of 12 μM. GSK3-IN-1 can be used in the research of diabetes. GSK3-IN-1  Chemical Structure
  18. GC66032 GSK-3β inhibitor 11 GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research. GSK-3β inhibitor 11  Chemical Structure
  19. GC66024 Aldometanib Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis. Aldometanib  Chemical Structure
  20. GC66013 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB). MOMIPP  Chemical Structure
  21. GC66002 PF-06685249 PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC50 of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 can be used for diabetic nephropathy research. PF-06685249  Chemical Structure
  22. GC65969 CHMFL-PI3KD-317 CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells. CHMFL-PI3KD-317  Chemical Structure
  23. GC65944 CC214-2 CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB. CC214-2  Chemical Structure
  24. GC65559 INY-03-041 INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor GDC-0068 conjugated to Lenalidomide (Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0 nM, 6.8 nM and 3.5 nM, respectively. INY-03-041  Chemical Structure
  25. GC65534 Boc-L-cyclobutylglycine Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis. Boc-L-cyclobutylglycine  Chemical Structure
  26. GC65507 AZD8154 AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. AZD8154  Chemical Structure
  27. GC65466 MS170 MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total AKT (T-AKT) with the DC50 value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with Kds of 1.3 nM, 77 nM, and 6.5 nM, respectively. MS170  Chemical Structure
  28. GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1  Chemical Structure
  29. GC65454 UCT943 UCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943  Chemical Structure
  30. GC65442 Musk ketone Musk ketone (MK) is a widely used artificial fragrance. Musk ketone  Chemical Structure
  31. GC65375 Phospho-Glycogen Synthase Peptide-2(substrate) TFA Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases. Phospho-Glycogen Synthase Peptide-2(substrate) TFA  Chemical Structure
  32. GC65367 Borussertib Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Aktwt. Borussertib  Chemical Structure
  33. GC65309 GSK-F1 GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1  Chemical Structure
  34. GC65249 STL127705 STL127705 (Compound L) is a potent Ku 70/80 heterodimer protein inhibitor with an IC50 of 3.5 μM. STL127705 interferes the binding of Ku70/80 to DNA and by inhibits the activation of the DNA-PKCS kinase. STL127705 shows antiproliferative and anticancer activity. STL127705 induces apoptosis. STL127705  Chemical Structure
  35. GC65199 PI3Kδ-IN-1 PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM. PI3Kδ-IN-1  Chemical Structure
  36. GC65149 AZD3458 AZD3458 is a potent and remarkably selective PI3Kγ inhibitor with pIC50s of 9.1, 5.1, <4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively. AZD3458  Chemical Structure
  37. GC65143 MKC-1 MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family. MKC-1  Chemical Structure
  38. GC65115 mTOR inhibitor-1 mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy. mTOR inhibitor-1  Chemical Structure
  39. GC64992 YH-306 YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization. YH-306  Chemical Structure
  40. GC64938 AZD-7648 AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity. AZD-7648  Chemical Structure
  41. GC64936 TD52 dihydrochloride TD52 dihydrochloride, an Erlotinib derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity. TD52 dihydrochloride  Chemical Structure
  42. GC64818 AMA-37 AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively. AMA-37  Chemical Structure
  43. GC64778 Gilmelisib Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC50 <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1. Gilmelisib  Chemical Structure
  44. GC64670 24-Methylenecycloartanyl ferulate 24-Methylenecycloartanyl ferulate is a γ-oryzanol compound. 24-Methylenecycloartanyl ferulate promotes parvin-beta expression in human breast cancer cells. 24-Methylenecycloartanyl ferulate is a potential ATP-competitive Akt1 inhibitor (EC50= 33.3μM). 24-Methylenecycloartanyl ferulate  Chemical Structure
  45. GC64612 GSK251 GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode. GSK251  Chemical Structure
  46. GC64402 MHY-1685 MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. MHY-1685  Chemical Structure
  47. GC52091 5,7-Dichlorothiazolo[5,4-d]pyrimidine A building block 5,7-Dichlorothiazolo[5,4-d]pyrimidine  Chemical Structure
  48. GC64377 Batatasin III Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities. Batatasin III  Chemical Structure
  49. GC64304 MTI-31 MTI-31 is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31  Chemical Structure
  50. GC64278 RP-3500 RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity. RP-3500  Chemical Structure
  51. GC64231 Vevorisertib trihydrochloride Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer. Vevorisertib trihydrochloride  Chemical Structure
  52. GC64223 Sophocarpine monohydrate Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine monohydrate  Chemical Structure
  53. GC64188 L-Leucine-d3 L-Leucine-d3 is the deuterium labeled L-Leucine. L-Leucine-d3  Chemical Structure
  54. GC64035 Hirsutenone Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone  Chemical Structure
  55. GC63934 Karanjin Karanjin is a major active furanoflavonol constituent of Fordia cauliflora. Karanjin induces GLUT4 translocation in skeletal muscle cells by increasing AMPK activity. Karanjin can induce cancer cell death through cell cycle arrest and enhance apoptosis. Karanjin  Chemical Structure
  56. GC63894 RMC-6272 RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. RMC-6272  Chemical Structure
  57. GC63833 L-Leucine-15N L-Leucine-15N  Chemical Structure
  58. GC63802 (R)-PS210 (R)-PS210, the R enantiomer of PS210 (compound 4h-eutomer), is a substrate-selective allosteric activator of PDK1 with an AC50 value of 1.8 μM. (R)-PS210 targets to the PIF-binding pocket of?PDK1. PIF: The protein kinase C-related kinase 2 (PRK2)-interacting fragment. (R)-PS210  Chemical Structure
  59. GC63539 CCT128930 hydrochloride CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity. CCT128930 hydrochloride  Chemical Structure
  60. GC63524 (32-Carbonyl)-RMC-5552 (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2). (32-Carbonyl)-RMC-5552  Chemical Structure
  61. GC63446 PF-04802367 PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367  Chemical Structure
  62. GC63391 CYH33 methanesulfonate CYH33 methanesulfonate is an orally active, highly selective PI3Kα inhibitor with IC50s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 methanesulfonate inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 methanesulfonate has potent activity against solid tumors. CYH33 methanesulfonate  Chemical Structure
  63. GC63210 TAS-117 TAS-117 is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). TAS-117 triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. TAS-117 induces apoptosis and autophagy. TAS-117  Chemical Structure
  64. GC63181 SAR502250 SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250  Chemical Structure
  65. GC63155 PS47 PS47 is an inactive E-isomer of PS48. PS47  Chemical Structure
  66. GC63122 NV-5138 hydrochloride NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 hydrochloride  Chemical Structure
  67. GC63121 NV-5138 NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138  Chemical Structure
  68. GC63017 IHMT-PI3Kδ-372 IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372  Chemical Structure
  69. GC62973 FD223 FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML. FD223  Chemical Structure
  70. GC62875 BRD3731 BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731  Chemical Structure
  71. GC62841 AMPK activator 4 AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4  Chemical Structure
  72. GC62736 (E/Z)-GSK-3β inhibitor 1 (E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. (E/Z)-GSK-3β inhibitor 1  Chemical Structure
  73. GC49440 ML-9 A PKB/Akt inhibitor ML-9  Chemical Structure
  74. GC49392 CHIR98024 A GSK3 inhibitor CHIR98024  Chemical Structure
  75. GC62661 PF-07104091 hydrate PF-07104091 hydrate  Chemical Structure
  76. GC62660 PF-07104091 PF-07104091  Chemical Structure
  77. GC62649 RMC-5552 RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity. RMC-5552  Chemical Structure
  78. GC62630 TAS-117 hydrochloride TAS-117 hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). TAS-117 hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. TAS-117 hydrochloride induces apoptosis and autophagy. TAS-117 hydrochloride  Chemical Structure
  79. GC62593 Parsaclisib hydrochloride Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies. Parsaclisib hydrochloride  Chemical Structure
  80. GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM). hSMG-1 inhibitor 11e  Chemical Structure
  81. GC62556 PF-06843195 PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy. PF-06843195  Chemical Structure
  82. GC62548 COH-SR4 COH-SR4 is an AMPK activator. COH-SR4  Chemical Structure
  83. GC62521 PI3Kα-IN-4 PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity. PI3Kα-IN-4  Chemical Structure
  84. GC62495 DS-7423 DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. DS-7423  Chemical Structure
  85. GC62480 Zandelisib Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic. Zandelisib  Chemical Structure
  86. GC62465 Idelalisib D5 Idelalisib D5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor. Idelalisib D5  Chemical Structure
  87. GC62456 SRX3207 SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression. SRX3207  Chemical Structure
  88. GC62450 (S)-PI3Kα-IN-4 (S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer. (S)-PI3Kα-IN-4  Chemical Structure
  89. GC62423 GSK-3/CDK5/CDK2-IN-1 GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1  Chemical Structure
  90. GC62376 iMDK quarterhydrate iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice. iMDK quarterhydrate  Chemical Structure
  91. GC62342 TASP0415914 TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC50 of 29 nM. TASP0415914  Chemical Structure
  92. GC62340 PIK-108 PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor. PIK-108  Chemical Structure
  93. GC62339 mTOR inhibitor-8 mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells. mTOR inhibitor-8  Chemical Structure
  94. GC62338 GSK-3β inhibitor 3 GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia. GSK-3β inhibitor 3  Chemical Structure
  95. GC62335 AZ2 AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3). AZ2  Chemical Structure
  96. GC62191 TD52 TD52, an Erlotinib derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity. TD52  Chemical Structure
  97. GC62190 AKT-IN-6 AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1). AKT-IN-6  Chemical Structure
  98. GC62164 BAY1082439 BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth. BAY1082439  Chemical Structure
  99. GC62141 NVS-PI3-4 NVS-PI3-4 is a specific PI3Kγ inhibitor. NVS-PI3-4  Chemical Structure
  100. GC62140 PKI-179 PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo. PKI-179  Chemical Structure
  101. GC62135 BC1618 BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618  Chemical Structure

Items 1 to 100 of 560 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction